IGC
Price
$0.35
Change
+$0.02 (+6.06%)
Updated
Jul 17, 04:59 PM (EDT)
Capitalization
28.03M
22 days until earnings call
RYTM
Price
$90.67
Change
-$0.77 (-0.84%)
Updated
Jul 17, 04:59 PM (EDT)
Capitalization
6.03B
19 days until earnings call
Interact to see
Advertisement

IGC vs RYTM

Header iconIGC vs RYTM Comparison
Open Charts IGC vs RYTMBanner chart's image
IGC Pharma
Price$0.35
Change+$0.02 (+6.06%)
Volume$100
Capitalization28.03M
Rhythm Pharmaceuticals
Price$90.67
Change-$0.77 (-0.84%)
Volume$2.64K
Capitalization6.03B
IGC vs RYTM Comparison Chart in %
Loading...
IGC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RYTM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IGC vs. RYTM commentary
Jul 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IGC is a Hold and RYTM is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 18, 2025
Stock price -- (IGC: $0.33 vs. RYTM: $91.44)
Brand notoriety: IGC and RYTM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IGC: 68% vs. RYTM: 95%
Market capitalization -- IGC: $28.03M vs. RYTM: $6.03B
IGC [@Biotechnology] is valued at $28.03M. RYTM’s [@Biotechnology] market capitalization is $6.03B. The market cap for tickers in the [@Biotechnology] industry ranges from $300.78B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IGC’s FA Score shows that 0 FA rating(s) are green whileRYTM’s FA Score has 1 green FA rating(s).

  • IGC’s FA Score: 0 green, 5 red.
  • RYTM’s FA Score: 1 green, 4 red.
According to our system of comparison, both IGC and RYTM are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IGC’s TA Score shows that 6 TA indicator(s) are bullish while RYTM’s TA Score has 6 bullish TA indicator(s).

  • IGC’s TA Score: 6 bullish, 4 bearish.
  • RYTM’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both IGC and RYTM are a good buy in the short-term.

Price Growth

IGC (@Biotechnology) experienced а -8.72% price change this week, while RYTM (@Biotechnology) price change was +2.74% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.06%. For the same industry, the average monthly price growth was +13.69%, and the average quarterly price growth was +40.92%.

Reported Earning Dates

IGC is expected to report earnings on Nov 12, 2025.

RYTM is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+2.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RYTM($6.03B) has a higher market cap than IGC($28M). RYTM YTD gains are higher at: 63.344 vs. IGC (-0.565). IGC has higher annual earnings (EBITDA): -7.58M vs. RYTM (-145.8M). RYTM has more cash in the bank: 314M vs. IGC (470K). IGC has less debt than RYTM: IGC (270K) vs RYTM (4.06M). RYTM has higher revenues than IGC: RYTM (137M) vs IGC (1.24M).
IGCRYTMIGC / RYTM
Capitalization28M6.03B0%
EBITDA-7.58M-145.8M5%
Gain YTD-0.56563.344-1%
P/E RatioN/AN/A-
Revenue1.24M137M1%
Total Cash470K314M0%
Total Debt270K4.06M7%
FUNDAMENTALS RATINGS
IGC vs RYTM: Fundamental Ratings
IGC
RYTM
OUTLOOK RATING
1..100
9027
VALUATION
overvalued / fair valued / undervalued
1..100
48
Fair valued
98
Overvalued
PROFIT vs RISK RATING
1..100
10020
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
5036
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IGC's Valuation (48) in the Biotechnology industry is somewhat better than the same rating for RYTM (98). This means that IGC’s stock grew somewhat faster than RYTM’s over the last 12 months.

RYTM's Profit vs Risk Rating (20) in the Biotechnology industry is significantly better than the same rating for IGC (100). This means that RYTM’s stock grew significantly faster than IGC’s over the last 12 months.

IGC's SMR Rating (98) in the Biotechnology industry is in the same range as RYTM (100). This means that IGC’s stock grew similarly to RYTM’s over the last 12 months.

RYTM's Price Growth Rating (36) in the Biotechnology industry is in the same range as IGC (50). This means that RYTM’s stock grew similarly to IGC’s over the last 12 months.

RYTM's P/E Growth Rating (100) in the Biotechnology industry is in the same range as IGC (100). This means that RYTM’s stock grew similarly to IGC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IGCRYTM
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 8 days ago
83%
Bullish Trend 2 days ago
80%
Declines
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 22 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 2 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
IGC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RYTM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BGEIX18.65N/A
N/A
American Century Global Gold Inv
FIKDX12.03N/A
N/A
Kempner Multi-Cap Deep Value Instl
MGGPX37.34N/A
N/A
Morgan Stanley Inst Global Opp A
FDGRX42.76N/A
N/A
Fidelity Growth Company Fund
HWLZX42.90N/A
N/A
Hotchkis & Wiley Large Cap Fdml Value Z

IGC and

Correlation & Price change

A.I.dvisor indicates that over the last year, IGC has been loosely correlated with TECX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if IGC jumps, then TECX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IGC
1D Price
Change %
IGC100%
-1.62%
TECX - IGC
49%
Loosely correlated
+5.27%
KZR - IGC
34%
Loosely correlated
-2.60%
MRNA - IGC
31%
Poorly correlated
+1.52%
RYTM - IGC
31%
Poorly correlated
+2.33%
ANVS - IGC
30%
Poorly correlated
+2.24%
More

RYTM and

Correlation & Price change

A.I.dvisor indicates that over the last year, RYTM has been loosely correlated with CRNX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if RYTM jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RYTM
1D Price
Change %
RYTM100%
+2.33%
CRNX - RYTM
46%
Loosely correlated
+0.22%
VRNA - RYTM
45%
Loosely correlated
-0.03%
RVMD - RYTM
44%
Loosely correlated
+1.56%
IDYA - RYTM
44%
Loosely correlated
+3.36%
NRIX - RYTM
43%
Loosely correlated
+2.22%
More